V.I. ILYINSKIY¹, O.V. SKOROKHODKINA², A.R. VALEEVA²

¹Republican Clinical Hospital, 138 Orenburgskiy tract, Kazan, Russian Federation, 420064

²Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation, 420012

Ilyinskiy V.I. — Head of the Department of Pulmonology, tel. +7-987-296-26-13, e-mai: ilinskiy1960@mail.ru¹

Skorokhodkina O.V. — D. Med. Sc., Professor of the Department of Clinical Immunology and Allergology, tel. +7-917-392-50-45, e-mail: olesya27@rambler.ru²

Valeeva A.R. — Resident Doctor of the Department of Clinical Immunology and Allergology, tel. +7-917-911-70-10, e-mail: aliv05@mail.ru²

The article presents results of clinical observation of a patient with severe persistent allergic asthma treated with omalizumab. Omalizumab is a treatment option for patients with moderate to severe allergic asthma in cases when the symptoms are poorly controlled with inhaled corticosteroids. Treatment with omalizumab resulted in improvement of both the disease symptoms and respiratory function indicators. It is concluded that the addition of omalizumab decreases the doses of corticosteroids and allows to achieve control over the disease.

Key words: severe persistent allergic asthma, omalizumab.

REFERENCES

1. Kolbin A.S., Klimko N.N., Andreev B.V. Clinical and economic rationale for the use Xolair (omalizumab) in bronchial asthma.Kachestvennaya klinicheskaya praktika, 2008, no. 2, pp. 53-61 (in Russ.).

2. Global Initiative for Asthma. Workshop Report, 2011.

3. Soler M., Matz J., Townley R. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.Eur Respir. J., 2001, 18, rr. 254 261.

4. Burkovskaya E.N. New approaches to the treatment of severe asthma.Novye metody diagnostiki i lecheniya, 2008, no. 1, pp. 53-56 (in Russ.).

5. Knyazheskaya N.P. Ksolar (omalizumab) v terapii bronkhial’noy astmy [Xolair (omalizumab) in the treatment of bronchial asthma]Pul’monologiya detskogo vozrasta: problemy i resheniya. Moscow, 2007. Issue 7. Pp. 151-153.